BIOMARIN PHARMACEUTICAL BCG MATRIX TEMPLATE RESEARCH
Unlock Strategic Clarity
BioMarin's product portfolio sits at an inflection point-blockbuster enzyme-replacement therapies act like Cash Cows funding high-risk, high-reward gene therapy Question Marks; pipeline orphan drugs could be Stars if uptake and pricing align. This preview highlights shifting market share dynamics, regulatory tailwinds, and capital allocation tensions managers must resolve. Dive deeper into this company's BCG Matrix and gain a clear view of where its products stand-Stars, Cash Cows, Dogs, or Question Marks. Purchase the full version for a complete breakdown and strategic insights you can act on.
Stars
VOXZOGO (Achondroplasia)
VOXZOGO (achondroplasia) is BioMarin Pharmaceutical's primary growth engine, delivering $927 million in 2025 revenue, up 26% year-over-year, and holding first-and-only global pharmacologic market leadership.
About 73% of 2025 sales came from ex‑US markets, and BioMarin completed Phase 3 enrollment for hypochondroplasia in April 2025 to expand the addressable population.
PALYNZIQ (Phenylketonuria)
PALYNZIQ became a Star by end-2025, posting 22% revenue growth and four straight quarters of double-digit momentum, driving 2025 sales to about $425 million.
Early-2026 label expansion to adolescents 12-17 followed a positive Phase 3, unlocking an estimated incremental addressable market of ~25,000 patients in developed markets.
As the only enzyme substitute that lowers blood phenylalanine (Phe) to normal range, PALYNZIQ increased market share to roughly 38% of treated PKU patients by Q4‑2025.
BMN 333 (Long-acting CNP)
BMN 333 is a next-generation Star in BioMarin Pharmaceutical's skeletal franchise, engineered for less-frequent dosing and a potentially superior clinical profile versus VOXZOGO.
Year-end 2025 PK data showed sustained concentrations 2-3x higher than prior analogs in preclinical models, supporting dosing advantages.
BioMarin plans pivotal Phase 2/3 enrollment in early 2026 to position BMN 333 to succeed VOXZOGO and defend >70% skeletal market share against emerging oral rivals.
Acquired Amicus Portfolio (Galafold & Pombiliti)
Following BioMarin Pharmaceutical's $4.8 billion acquisition of Amicus Therapeutics announced in late 2025, Galafold and the Pombiliti + Opfolda combo enter as Stars-high-growth, market-established assets.
Galafold (Fabry) and Pombiliti + Opfolda (Pompe) are forecast to boost BioMarin's 2026 revenue run-rate by about $450-600 million, adding high-margin rare-disease sales tied to existing U.S./EU commercial channels.
They broaden BioMarin's rare-disease portfolio, improve margin mix, and leverage the company's Q2 2026 integration to accelerate growth and payer access.
- $4.8B purchase price
- Est. $450-600M incremental 2026 run-rate
- High gross margins, rare-disease pricing
- Integration closing Q2 2026
International Market Expansion
BioMarin Pharmaceutical's international commercial platform functions as a Star, with launches in over 55 markets by end-2025 and a tailored rare-disease go-to-market model that preserves high market share where patient ID and reimbursement are barriers.
Large government contracts, especially in Latin America, helped drive a 17% rise in Q4 total revenues to $875 million, highlighting scalable demand capture outside the U.S.
The global infrastructure-market access teams, patient-finding programs, and local manufacturing partnerships-reduces time-to-revenue and deters new entrants in niche rare-disease segments.
- 55+ markets launched by 2025
- Q4 revenue up 17% to $875M
- Strength: government procurement in Latin America
- Barrier: patient ID and reimbursement expertise
BioMarin's 2025 stars: VOXZOGO $927M, PALYNZIQ $425M; Amicus buy boosts 2026 run‑rate
VOXZOGO $927M (2025) and PALYNZIQ $425M (2025) drive BioMarin's Stars; BMN 333 advancing Phase 2/3 (early‑2026) to defend >70% skeletal share; Amicus buy ($4.8B) adds Galafold/Pombiliti+Opfolda, est. $450-600M 2026 run‑rate; 55+ markets, Q4 revenue $875M (+17%).
| Asset | 2025/$ | Notes |
|---|---|---|
| VOXZOGO | $927M | 26% YoY, ex‑US 73% |
| PALYNZIQ | $425M | 38% PKU share |
| Amicus assets | $450-600M | 2026 run‑rate |
What is included in the product
Detailed Word Document
Portfolio mapping shows Stars (growth enzyme therapies), Cash Cows (legacy PKU assets), Question Marks (gene therapies), Dogs (low-demand niche drugs) with invest/hold/divest guidance.
Customizable Excel Spreadsheet
One-page overview placing each BioMarin business unit in a quadrant as a concise pain-point reliever for strategic clarity.
Cash Cows
VIMIZIM (Morquio A Syndrome)
VIMIZIM (for Morquio A) is a cornerstone Cash Cow for BioMarin Pharmaceutical, contributing materially to the $2.1 billion total enzyme therapy revenue in 2025 and delivering high gross margins and steady free cash flow.
In a mature, low-growth market VIMIZIM still grew 7% in 2025-driven by sustained patient adherence and timing of large government orders-funding BioMarin's R&D and strategic acquisitions.
NAGLAZYME (MPS VI)
NAGLAZYME (MPS VI) remains a classic cash cow for BioMarin Pharmaceutical, delivering steady returns from a global patient base; favorable international order timing in 2025 helped the enzyme franchise grow 9% year-over-year.
As a mature therapy requiring minimal new marketing spend, NAGLAZYME was a key contributor to BioMarin's $828 million operating cash flow in FY2025.
ALDURAZYME (MPS I)
ALDURAZYME (MPS I), commercialized via a joint venture with Sanofi, delivers a high market share in the mucopolysaccharidosis I segment and remained a steady contributor to BioMarin's 2025 revenue stream.
After a 40% year-over-year revenue spike in 2024 driven by order timing (peaking at roughly $150m in 2024 revenue), sales normalized in 2025 to a consistent cash-generating profile near $110m.
With minimal capital expenditure needs, ALDURAZYME frees cash to service BioMarin's debt and fund new launches, effectively acting as a classic cash cow within the BCG matrix.
BRINEURA (CLN2 Disease)
BRINEURA (cerliponase alfa) is a Cash Cow for BioMarin Pharmaceutical, holding the leading share in CLN2 (neuronal ceroid lipofuscinosis type 2) treatment as the first approved therapy, generating steady high-margin revenue despite an ultra-rare patient pool.
Its premium pricing and strong retention produced reliable cash flows and supported a 13% Q4 2025 enzyme-therapy revenue rise, underscoring BRINEURA's funding role for R&D and operations.
- First CLN2 therapy; market leader
- Ultra-rare patients; growth capped
- High price; strong retention = steady margins
- Contributed to 13% Q4 2025 enzyme-therapy growth
KUVAN (Phenylketonuria)
KUVAN (sapropterin) remains a legacy Cash Cow for BioMarin Pharmaceutical, generating residual royalties and brand-loyal sales despite generic entry and declining volumes; BioMarin classifies it within Other Revenues, forecasted at $100-$125 million for 2026.
With minimal promotional spend required, KUVAN margins convert nearly all revenue into operating income-helping sustain cash flow while resources shift to growth assets like Roctavian and Hemophilia programs.
- Legacy product with generic competition
- Included in Other Revenues: $100-$125M projected for 2026
- Declining sales but steady royalties and brand loyalty
- Minimal promotion → high operating margin conversion
BioMarin's enzyme cash cows drove $2.1B in 2025-strong OCF and upbeat 2026 guidance
VIMIZIM, NAGLAZYME, ALDURAZYME, BRINEURA and KUVAN generated steady high-margin cash flows in FY2025-enzyme therapies drove $2.1B revenue, BioMarin's operating cash flow was $828M, ALDURAZYME ≈$110M in 2025, BRINEURA up 13% in Q4 2025, KUVAN Other Revenues guide $100-$125M for 2026.
| Product | FY2025 | Role |
|---|---|---|
| VIMIZIM | Part of $2.1B | Cash Cow |
| NAGLAZYME | ↑9% 2025 | Cash Cow |
| ALDURAZYME | $110M | Cash Cow |
| BRINEURA | Q4↑13% | Cash Cow |
| KUVAN | $100-$125M(2026) | Legacy Cash Cow |
What You See Is What You Get
BioMarin Pharmaceutical BCG Matrix
The file you're previewing is the exact BioMarin BCG Matrix report you'll receive after purchase-no watermarks, no demo content-just a fully formatted, analysis-ready document built for strategic clarity and professional use.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Unlock Strategic Clarity
BioMarin's product portfolio sits at an inflection point-blockbuster enzyme-replacement therapies act like Cash Cows funding high-risk, high-reward gene therapy Question Marks; pipeline orphan drugs could be Stars if uptake and pricing align. This preview highlights shifting market share dynamics, regulatory tailwinds, and capital allocation tensions managers must resolve. Dive deeper into this company's BCG Matrix and gain a clear view of where its products stand-Stars, Cash Cows, Dogs, or Question Marks. Purchase the full version for a complete breakdown and strategic insights you can act on.
Stars
VOXZOGO (Achondroplasia)
VOXZOGO (achondroplasia) is BioMarin Pharmaceutical's primary growth engine, delivering $927 million in 2025 revenue, up 26% year-over-year, and holding first-and-only global pharmacologic market leadership.
About 73% of 2025 sales came from ex‑US markets, and BioMarin completed Phase 3 enrollment for hypochondroplasia in April 2025 to expand the addressable population.
PALYNZIQ (Phenylketonuria)
PALYNZIQ became a Star by end-2025, posting 22% revenue growth and four straight quarters of double-digit momentum, driving 2025 sales to about $425 million.
Early-2026 label expansion to adolescents 12-17 followed a positive Phase 3, unlocking an estimated incremental addressable market of ~25,000 patients in developed markets.
As the only enzyme substitute that lowers blood phenylalanine (Phe) to normal range, PALYNZIQ increased market share to roughly 38% of treated PKU patients by Q4‑2025.
BMN 333 (Long-acting CNP)
BMN 333 is a next-generation Star in BioMarin Pharmaceutical's skeletal franchise, engineered for less-frequent dosing and a potentially superior clinical profile versus VOXZOGO.
Year-end 2025 PK data showed sustained concentrations 2-3x higher than prior analogs in preclinical models, supporting dosing advantages.
BioMarin plans pivotal Phase 2/3 enrollment in early 2026 to position BMN 333 to succeed VOXZOGO and defend >70% skeletal market share against emerging oral rivals.
Acquired Amicus Portfolio (Galafold & Pombiliti)
Following BioMarin Pharmaceutical's $4.8 billion acquisition of Amicus Therapeutics announced in late 2025, Galafold and the Pombiliti + Opfolda combo enter as Stars-high-growth, market-established assets.
Galafold (Fabry) and Pombiliti + Opfolda (Pompe) are forecast to boost BioMarin's 2026 revenue run-rate by about $450-600 million, adding high-margin rare-disease sales tied to existing U.S./EU commercial channels.
They broaden BioMarin's rare-disease portfolio, improve margin mix, and leverage the company's Q2 2026 integration to accelerate growth and payer access.
- $4.8B purchase price
- Est. $450-600M incremental 2026 run-rate
- High gross margins, rare-disease pricing
- Integration closing Q2 2026
International Market Expansion
BioMarin Pharmaceutical's international commercial platform functions as a Star, with launches in over 55 markets by end-2025 and a tailored rare-disease go-to-market model that preserves high market share where patient ID and reimbursement are barriers.
Large government contracts, especially in Latin America, helped drive a 17% rise in Q4 total revenues to $875 million, highlighting scalable demand capture outside the U.S.
The global infrastructure-market access teams, patient-finding programs, and local manufacturing partnerships-reduces time-to-revenue and deters new entrants in niche rare-disease segments.
- 55+ markets launched by 2025
- Q4 revenue up 17% to $875M
- Strength: government procurement in Latin America
- Barrier: patient ID and reimbursement expertise
BioMarin's 2025 stars: VOXZOGO $927M, PALYNZIQ $425M; Amicus buy boosts 2026 run‑rate
VOXZOGO $927M (2025) and PALYNZIQ $425M (2025) drive BioMarin's Stars; BMN 333 advancing Phase 2/3 (early‑2026) to defend >70% skeletal share; Amicus buy ($4.8B) adds Galafold/Pombiliti+Opfolda, est. $450-600M 2026 run‑rate; 55+ markets, Q4 revenue $875M (+17%).
| Asset | 2025/$ | Notes |
|---|---|---|
| VOXZOGO | $927M | 26% YoY, ex‑US 73% |
| PALYNZIQ | $425M | 38% PKU share |
| Amicus assets | $450-600M | 2026 run‑rate |
What is included in the product
Detailed Word Document
Portfolio mapping shows Stars (growth enzyme therapies), Cash Cows (legacy PKU assets), Question Marks (gene therapies), Dogs (low-demand niche drugs) with invest/hold/divest guidance.
Customizable Excel Spreadsheet
One-page overview placing each BioMarin business unit in a quadrant as a concise pain-point reliever for strategic clarity.
Cash Cows
VIMIZIM (Morquio A Syndrome)
VIMIZIM (for Morquio A) is a cornerstone Cash Cow for BioMarin Pharmaceutical, contributing materially to the $2.1 billion total enzyme therapy revenue in 2025 and delivering high gross margins and steady free cash flow.
In a mature, low-growth market VIMIZIM still grew 7% in 2025-driven by sustained patient adherence and timing of large government orders-funding BioMarin's R&D and strategic acquisitions.
NAGLAZYME (MPS VI)
NAGLAZYME (MPS VI) remains a classic cash cow for BioMarin Pharmaceutical, delivering steady returns from a global patient base; favorable international order timing in 2025 helped the enzyme franchise grow 9% year-over-year.
As a mature therapy requiring minimal new marketing spend, NAGLAZYME was a key contributor to BioMarin's $828 million operating cash flow in FY2025.
ALDURAZYME (MPS I)
ALDURAZYME (MPS I), commercialized via a joint venture with Sanofi, delivers a high market share in the mucopolysaccharidosis I segment and remained a steady contributor to BioMarin's 2025 revenue stream.
After a 40% year-over-year revenue spike in 2024 driven by order timing (peaking at roughly $150m in 2024 revenue), sales normalized in 2025 to a consistent cash-generating profile near $110m.
With minimal capital expenditure needs, ALDURAZYME frees cash to service BioMarin's debt and fund new launches, effectively acting as a classic cash cow within the BCG matrix.
BRINEURA (CLN2 Disease)
BRINEURA (cerliponase alfa) is a Cash Cow for BioMarin Pharmaceutical, holding the leading share in CLN2 (neuronal ceroid lipofuscinosis type 2) treatment as the first approved therapy, generating steady high-margin revenue despite an ultra-rare patient pool.
Its premium pricing and strong retention produced reliable cash flows and supported a 13% Q4 2025 enzyme-therapy revenue rise, underscoring BRINEURA's funding role for R&D and operations.
- First CLN2 therapy; market leader
- Ultra-rare patients; growth capped
- High price; strong retention = steady margins
- Contributed to 13% Q4 2025 enzyme-therapy growth
KUVAN (Phenylketonuria)
KUVAN (sapropterin) remains a legacy Cash Cow for BioMarin Pharmaceutical, generating residual royalties and brand-loyal sales despite generic entry and declining volumes; BioMarin classifies it within Other Revenues, forecasted at $100-$125 million for 2026.
With minimal promotional spend required, KUVAN margins convert nearly all revenue into operating income-helping sustain cash flow while resources shift to growth assets like Roctavian and Hemophilia programs.
- Legacy product with generic competition
- Included in Other Revenues: $100-$125M projected for 2026
- Declining sales but steady royalties and brand loyalty
- Minimal promotion → high operating margin conversion
BioMarin's enzyme cash cows drove $2.1B in 2025-strong OCF and upbeat 2026 guidance
VIMIZIM, NAGLAZYME, ALDURAZYME, BRINEURA and KUVAN generated steady high-margin cash flows in FY2025-enzyme therapies drove $2.1B revenue, BioMarin's operating cash flow was $828M, ALDURAZYME ≈$110M in 2025, BRINEURA up 13% in Q4 2025, KUVAN Other Revenues guide $100-$125M for 2026.
| Product | FY2025 | Role |
|---|---|---|
| VIMIZIM | Part of $2.1B | Cash Cow |
| NAGLAZYME | ↑9% 2025 | Cash Cow |
| ALDURAZYME | $110M | Cash Cow |
| BRINEURA | Q4↑13% | Cash Cow |
| KUVAN | $100-$125M(2026) | Legacy Cash Cow |
What You See Is What You Get
BioMarin Pharmaceutical BCG Matrix
The file you're previewing is the exact BioMarin BCG Matrix report you'll receive after purchase-no watermarks, no demo content-just a fully formatted, analysis-ready document built for strategic clarity and professional use.
